There are many different ways to diagnose cancer. Cancer diagnostic testing involves tests and procedures to confirm the presence of disease and identify the correct tumor type, location, extent and stage. The most common diagnostic tests include biopsy tests (bone marrow, endoscopic, needle biopsy), endoscopy tests (bronchoscopy, colonoscopy, colposcopy, sigmoidoscopy, etc.), diagnostic imaging (CT, MRI, PET, mammography, ultrasound, etc.), and detection of cancer-specific tumor biomarkers. Benign tumors are slow growing tumors and do not invade into other tissues while the malignant tumors are characterized by rapid growth, invasiveness, and potential to colonize in distant organs. The rising prevalence of cancer across the globe is driving the global cancer diagnostics market, whereas higher incidences of cancer and increasing healthcare spending is expected to aid the global tissue diagnostics market.
The global cancer diagnostics market report estimates the market size (Revenue USD million – 2014 to 2021) for market segmentation based on testing methods and their applications (organ or cell-specific cancer types – blood, breast, colorectal, kidney, liver, lung, ovarian, pancreatic, and prostate cancer) and forecasts growth trends (CAGR% – 2017 to 2021).
The global cancer diagnostics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global cancer diagnostics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global cancer diagnostics market and included in this report are Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Genentech, Genoptix (Novartis), and Roche Diagnostics.